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Potential inhibitors of a target biomolecule, NAD-dependent deacetylase Sirtuin 1, were identified 
by a contest-based approach, in which participants were asked to propose a prioritized list of 400 
compounds from a designated compound library containing 2.5 million compounds using in silico 
methods and scoring. Our aim was to identify target enzyme inhibitors and to benchmark computer-
aided drug discovery methods under the same experimental conditions. Collecting compound 
lists derived from various methods is advantageous for aggregating compounds with structurally 
diversified properties compared with the use of a single method. The inhibitory action on Sirtuin 1 
of approximately half of the proposed compounds was experimentally accessed. Ultimately, seven 
structurally diverse compounds were identified.
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In the early stages of the drug discovery process, active compounds, inhibitors and/or activators, for a target bio-
molecule are sought. The high-throughput screening (HTS) campaign can be experimentally used to identify as 
many active compounds as possible from a compound library. However, the odds of finding active compounds 
using HTS is low. A previous study concluded that the success rate ranges from 0.05% to 0.14% depending on the 
class of target biomolecule (kinase, GPCR, protein-protein interaction, etc.)1. To improve odds, computer-aided 
drug discovery or virtual screening (VS) methods have been employed2,3.
VS methods utilize structural information of a target biomolecule and/or experimentally known actives/
inactives. The former is known as structure-based VS (SBVS), and the latter, as ligand-based VS (LBVS). The 
representative of SBVS is docking study, which docks test compounds to a modeled target biomolecule. There 
are many parameters that are used in docking studies to determine the ranking of test compounds, e.g., how the 
target biomolecule is modeled, whether the target biomolecules are treated as a rigid body or a flexible body, how 
the compounds of interest are oriented in relation to the target molecule, and how the score of the placed com-
pound is defined4,5. LBVS is based on a hypothesis that test compounds with similar properties of known actives 
would have similar activities. To rank the test compounds, a simple comparison of the similarity of the chemical 
structure or structure-activity relationship (SAR) using actives and inactives is performed6. Combining LBVS and 
SBVS is also common2.
Performance comparisons of various VS methods have been addressed using known active/inactive com-
pounds; in other words, benchmarks have been conducted retrospectively7. Such benchmark results have led to 
obscure outcomes when VS methods are used in a prospective way. In addition, the performance of VS methods 
differs under various conditions, and no set standard exists8. Hence, currently we are not supplied with enough 
knowledge for choosing a suitable method for a designated compound library and target biomolecule before 
experimental validation.
Utilizing various VS methods for a certain problem is an alternative approach for relying on a single VS 
approach. For the various methods, we conducted two compound screening contests, in which participants 
were asked to propose potential active compounds of a target biomolecule from commercially available 2.2- and 
2.4-million compound lists. The inhibitory functions of the proposed compounds were experimentally assessed. 
In the first and second contests held in 20149 and 201510, respectively, we identified several hit compounds with 
inhibitory activity of the target molecule, i.e., the tyrosine-protein kinase Yes. Participants employed various 
methods. In the second contest, we found that iterating the contest with the same target would give improved hit 
rates and enable identification of the statistically warranted method.
To verify robustness of the concept of the contest-based approach, we conducted another contest in 2016 
employing a new target biomolecule, nicotinamide adenine dinucleotide (NAD)-dependent deacetylase Sirtuin 1, 
hereafter referred to as Sirtuin 1. Sirtuin 1 is a member of the sirtuin family (Sirtuin 1 to Sirtuin 7). The structure 
of Sirtuin 1 changes from an open state to a closed state upon the addition of cofactor (NAD+) and a substrate, 
and both open and closed structures have been reported (PDBID: 4IG9, 4KXQ)11. Other relevant structural infor-
mation is also available (see Table 1). Information of actives and inactives has been deposited in open databases, 
such as BindingDB12,13 and ChEMBL14. Histone deacetylase (HDAC) inhibitors and decoys were previously com-
piled in the MUBD-HDACs database, in which information of Sirtuin 1 is included15. Hence, SBVS and LBVS can 
be employed for the target.
The third compound screening contest was organized by the Initiative for Parallel Bioinformatics (IPAB). 
The submission period of compound proposals started in January 20, 2016, and ended in May 20, 2016. Sixteen 
groups participated in the contest. The participants were asked to propose a prioritized set of 400 compounds. We 
selected approximately 200 compounds from each group and, in total, 3,192 unique compounds were assayed. 
Seven potent compounds with half-maximal inhibitory concentrations (IC50) less than 20 μM were identified. The 
benefits of collecting proposed compounds via various methods are discussed in the following.
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Methods
Preparation of the compound library. To create a compound library for the contest, we obtained a com-
pound library from Enamine Ltd., which listed 2,459,912 available compounds in their inventory. We searched 
this inventory for compounds that were reported to interact or not interact with Sirtuin 1 to 7 in BindingDB12,13 
and ChEMBL version 2016. We found 1,443 unique compounds, among which 44 compounds in the compound 
library were eliminated. Finally, the compound library used in the contest contained 2,459,868 compounds, 
which was distributed to the participants of the contest.
Methods used by the participants. Sixteen groups participated in the contest, proposing various meth-
ods as shown in Table 1. Proposed compounds in canonical SMILES format with prioritized ranking are given in 
the supporting materials. Here, we briefly describe each method.
Group 1 (G1). Compounds in the library were first filtered by two-dimensional (2D) similarity with six 
known drugs for the target using SIMCOMP17. The top 20% of similar compounds were selected and used for 
structure-based virtual screening. The human Sirtuin 1 crystal structure (PDBID: 4KXQ) was used as a receptor. 
From the prescreened compound library, PL-PatchSurfer218 was used to select the top 2,000 molecules. These 
molecule were docked to Sirtuin 1 by AutoDock Vina19. The compounds were ranked by a sum of Z-scores from 
each program.
Group 2 (G2). Compounds in the library were filtered by the Tanimoto coefficient of 0.8 for the active chemicals 
detected in ChEMBL in relation to the target protein (query: SIR1_HUMAN). The protein structure (PDBID: 
4BN520), containing cocrystalized coenzyme carba-nicotinamide-adenine-denucleotide (CNA) and ligand N-[2-
[3-(piperazin-1-ylmethyl)imidazo[2,1-B][1,3]thiazol-6-yl]phenyl]quinoxaline-2-carboxamide (SR7), was used 
to model a template protein with the FAMS program21. An in silico screening approach, ChooseLD22, was applied 
to the model. Both the original version and the hydrophobic interaction, including a version of ChooseLD, were 
used in the presence or absence of Coenzyme CNA. Then, four kinds of ChooseLD patterns were determined, 
among which highly ranked compounds were equally selected.
Group
Modeling of Sirtuin 1 structure
Ligand preparation
Processing method of compound library
3D structure modeling/
prediction methods/tools PDB ID used Filter class Actives Decoys
1 — 4KXQ11 OMEGA61 LB→SB Cambinol, HR73, salermide, sirtinol, suramin, and tenovin
2 HM (FAMS)21 4BN520 Open babel62 LB→SB Cocrystalized ligands in PDB and ChEMBL (IC50 < 1 μM)
—
3 — — PaDEL-Descriptor23 LB MUBD-HDACs63
4 — 4KXQ CORINA64 Hybrid (LB&SB) PubChem (CID703333, CID71459392) —
5 — 4ZZJ65 Open babel. Dock27 Hybrid (LB&SB) Known Sirtuin inhibitors —
6 — — RDKit66 LB
ChEMBL (CHEMBL4506, 
CHEMBL4462, CHEMBL4461), 
PubChem (AID 652115), BindingDB 
(Target = NAD-Dependent Deacetylase 
Sirtuin 1)
7 4IG9,
11 4IF6, 4ZZI,65 
4I5I,33 4ZZJ Ligprep
67 Hybrid (LB&SB) Cocrystalized ligands
8 MD (myPresto, cosgene37) 4ZZI myPresto (AM1, AM1BCC)  Hybrid (LB → SB) Selisistat (EX-527), Compound 28
35  —
9 HM and minimization (SWISS model, Foldit) 4ZZI
Open babel, Discovery 
Studio visualizer SB
10 HM (Prime)41,42
4ZZI (selected from 
4I5I, 4IF6, 4IG9, 4KXQ, 
4ZZI, 4ZZJ, 5BTR68)
LigPrep Hybrid (LB&SB) ChEMBL (IC50 < 20 μM)
ChEMBL 
(IC50 > 100 μM)
11 myPresto (tplgeneX)37,38 4I5I myPresto (create3D) SB EX-527 analogue33 DUD-E8
12 — — RDKit LB BindingDB ZINC47
13 MD 4I5I OMEGA Hybrid (LB, SB&visual inspection) Sun et al.
49 —
14 — 4ZZI LigandBOX52 Hybrid (LB & SB) 8 compounds including Splitomicin, Cambinol, Salerminde —
15 — 4I5I OMEGA Hybrid (LB&SB) Cocrystalized ligands in PDB (4I5I, 4ZZI, 4IF6) —
16 4ZZI Hybrid (LB → SB)
Table 1. Summary of the methods used by participating groups. Software names are given in italic. 
PDB = Protein Data Bank; LB = ligand-based; SB = structure-based; HM = homology modeling; 
MD = molecular dynamics simulation.
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Group 3 (G3). An SAR model was trained by utilizing Sirtuin 1 and HDAC inhibitors and decoys from the 
MUBD-HDACs database.15 In detail, 770 1D and 2D descriptors and 881 PubChem fingerprints through the 
PaDEL descriptor23 for compounds were generated. The extremely random tree algorithm24 was employed for 
learning SAR models. Next, a trained model was applied to the compound library to predict the compound activ-
ity. Finally, the top-ranked 400 compounds were proposed for further validation based on the predicted score.
Group 4 (G4). A series of rational methods was applied to screen the compound library against the target pro-
tein. The methods included SAR analysis, docking simulation, database mining, substructure searching and 
empirical inspection. For structure-based studies, a post refined protein model originally retrieved from PDB 
(PDBID: 4KXQ) was applied as a target structure. Multiple docking tools were used in the screening. Machine 
learning methods25,26 were then applied to assess the binding potentials and to identify the most predictive bind-
ing mode that originated from those docking tools.
Group 5 (G5). In total, 110,000 compounds were chosen from the compound library based on their structural 
similarity to known Sirtuin 1 inhibitors and Lipinski’s rule of five. To further screen the compounds, the complex 
structures of Sirtuin 1 (PDBID: 4ZZJ) with the selected compounds were modeled, and the grid scores were 
obtained by docking calculations with Dock6 program code27. A new measure named the Ligand Triangle (LT) 
score was also introduced, and the candidate compounds were ranked according to the square sum of the two 
scores.
Group 6 (G6). Assay data of not only Sirtuin 1 but also its paralogous enzymes were utilized to train a regression 
model using a transfer learning method. Here, activity values of the training data were standardized to inhibition 
rates at 20 μM using Hill’s equation28 under the assumption that the Hill coefficient is 1. Compounds with sim-
ilar physicochemical properties to those of known inhibitors were extracted from the library using a modified 
method of QED29,30. Inhibition rates of these compounds were predicted with the trained model24. Then, com-
pounds that were predicted to possess the highest inhibition rates were proposed.
Group 7 (G7). Structure- and pharmacophore-based approaches were used to identify Sirtuin 1 inhibitors. In 
the structure-based method, open (PDBID: 4IG9), closed (PDBID: 4IF6), and liganded (PDBID: 4ZZI, 4I5I, 
4ZZJ) conformations were used, and 500 compounds were shortlisted from the compound library. Clustering 
yielded 300 compounds with chemical diversity. In the pharmacophore-based approach,31,32 the cocrystallized 
structures of Sirtuin 1 with an inhibitor and a substrate were used to derive a pharmacophore with the features 
and the geometry suitable to bind the active site of Sirtuin 1. Hit-libraries that resulted from structure-based 
screenings were screened again using the pharmacophore to obtain 100 compounds with the best fitness. In total, 
400 compounds were submitted.
Group 8 (G8). Among the compound library, compounds that possess an amide or thioamide group bound to 
a ring, lactams and thiolactams were first extracted, considering previous SAR studies33–35. Then, nondrug-like 
compounds and smaller or larger compounds were excluded. A molecular dynamics (MD) simulation of the 
structure of Sirtuin 1 (PDB ID: 4ZZI) was performed, and multiple coordinates were obtained from the MD 
trajectory. myPresto36–38 and a cloud computing environment was utilized for the docking simulation. The results 
were scored by the multiple target screening (MTS) method.36 Finally, inappropriate structures were eliminated 
by visual inspection.
Group 9 (G9). An initial 3D structure of Sirtuin 1 was prepared by the SWISS model using the structure of 
Sirtuin 1 (PDBID: 4ZZI) as a modeling template39. To clean up structural error in the prepared model, sidechain 
structures were optimized by Foldit standalone version40. To reduce calculation costs, the compounds in the 
library were filtered by human inspection considering the Sirtuin 1 binding site condition. The filtered com-
pounds were evaluated by docking simulation (AutoDock Vina19 with PyRx 0.8.). Finally, possibly favorable com-
pounds were selected by visual inspection and scored by AutoDock Vina.
Group 10 (G10). Homology modeling by Prime41,42 was used to obtain the target protein structure. Seven 
homology models were evaluated by decoy docking of 122 known active compounds and 200 inactive compounds 
obtained from the ChEMBL database. Compounds in the library with a molecular weight less than 500 were 
screened by Glide SP mode docking43,44. Finally, the top 50,000 compounds were reranked by the SIEVE-Score,45 
and the similarity of the interaction energy between a compound and each amino acid residue compared with the 
known active and decoy compounds was evaluated.
Group 11 (G11). A Sirtuin 1 structure (PDBID: 4I5I) was chosen to carry out the docking simulation. 4I5I con-
tains a ligand that inhibits Sirtuin 1 activity (EX-527).33 Therefore, the place where the ligand was bound attracted 
our attention, and our group attempted to find molecules that could bind at that location. Ligand efficiencies 
of the compounds in the library were calculated using the myPresto system37,38. Then, after eliminating optical 
isomers, the top 400 compounds that had the highest ligand efficiency were chosen as molecules with inhibitory 
activity.
Group 12 (G12). RankSVM,46 a machine learning method for ranking prediction, was used to construct the 
prediction model. Training data consisted of two parts. One part comprised samples of compounds with an IC50 
report of Sirtuin 1, 2 and 3 in BindingDB. The other part comprised random samples from ZINC47 as pseudo 
inactive compound data. ECFP448 fingerprint was used as a feature vector. The cost parameter of RankSVM was 
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chosen from 2−17,2−15, …, 215 with 5-fold cross validation. The evaluation was based on the top-k version of nor-
malized discounted cumulative gain (NDCG) with a k of 100.
Group 13 (G13). First, LBVS was performed for the compound library using known actives described by Sun et al.49 
Then, the output compounds from LBVS were applied to ensemble-docking using Sirtuin 1 pockets prepared by 
MD simulation with the initial coordinate of PDBID: 4I5I. Top-ranked compounds in the ensemble docking were 
collected, and their docking poses were produced. The docking poses were visually presented to volunteer voters. 
The voters conducted visual inspection, and selected “good,” “bad,” or “no idea” for each of the docking poses. 
Finally, the compounds were reranked by the vote result.
Group 14 (G14). Three methods were employed: MTS (structure-based),36 machine-learning MTS (ML-MTS) 
(hybrid of structure-based and ligand-based),50 and docking score index (DSI) (ligand-based)51 methods using 
myPresto. A target protein structure (PDB ID: 4ZZI) was used in MTS and ML-MTS methods. Eight known 
inhibitors including Splitomicin and Cambinol were used in the ML-MTS and DSI methods. Calculations were 
performed for the compound library included in a ready-to-dock compound database, LigandBOX52.
Group 15 (G15). In the process of seeking inhibitors of the target protein, an LBSV method, VS-APPLE53,54, 
was used. While conventional ligand-based VS methods adopt single ligand as a template, VS-APPLE adopts the 
multiple-ligand template, which is composed of multiple ligands bound to the same pocket, as a template. Three 
ligands of the target protein were chosen and then each of them was used as a single template for independent VS. 
This procedure was performed, because only a few known protein-ligand complexes were available for the target 
in PDB and these ligands bind to different part of the binding pocket.
Group 16 (G16). ECFP1248 fingerprints of 514 Sirtuin 1 binders downloaded from BindingDB were gener-
ated and used to build lasso, elastic net, ridge and random forest machine learning models relating Ki. A 
protein-structure-based pharmacophore was generated as an alternative approach. The machine learning and 
pharmacophore models were applied to ECFP12 fingerprints of the compound library to predict Ki values. 
Prioritized 200-300 compounds from each of the methods above, together with hits from the similarity search 
using known active Sirtuin 1 binders were prepared. This protocol resulted in approximately 2,000 compounds. 
Finally, rescoring and clustering based on the docking of the compounds to the target protein (PDBID: 4ZZI) 
using GOLD were used to prioritize 400 representative compounds.
Screening of Compounds
Screening of potential inhibitors. Selection of compounds for assaying from the proposed lists and the 
flow of the assays are described in Fig. 1a,b. The experimental procedures are described in the supporting infor-
mation in detail. Here, we briefly describe the screening flow and results.
A total of 3,192 compounds extracted from the proposed lists were first screened by thermal shift assay (TSA), 
which determined a melting temperature shift (ΔTm) of Sirtuin 1 upon the addition of a test compound at a 
concentration of 10 µM (n = 1) with primary hit criteria of ΔTm > 0.45 K or ΔTm < −1.5 K. Primary hits (48 com-
pounds) were retested in the same assay at three concentrations (5, 10, 20 µM, n = 4) for hit confirmation and for 
dose-dependency check. Secondary hits (41 compounds) were checked their selectivity for Sirtuin 1 based on 
counterscreening on unrelated protein targets (bovine carbonic anhydrase (CA) and recombinant SH2 domain 
of hABL1 kinase (ABL1)) at three different concentrations (5, 10, 20 µM, n = 4), which yielded 38 hit compounds, 
hereafter referred to as TSA hits. The TSA screening above was conducted in the absence of NAD+. As noted, the 
structure of Sirtuin 1 is different in the presence of NAD+ and substrate. The chemical profile of TSA hits found 
from the different conditions could be different. Hence, we applied the same TSA in the presence of NAD+ to the 
3,192 compounds. As a result, 39 TSA hits were found. Regardless of the presence of NAD+, 29 compounds were 
shared in both TSA hits.
The 48 ( = 38 + 39 −29) unique TSA hits were evaluated by an inhibitory assay, which determined inhibition 
rates of enzymatic activity of Sirtuin 1 of the test compounds at a concentration of 10 µM (n = 4) with a hit cri-
terion of an inhibitory rate >15%. Note that the inhibitory assay was conducted with NAD+. As a result, 20 hit 
compounds, 12 from TSA without NAD+ and 16 from TSA with NAD+, were found. An IC50 determination of 
the 20 hits was conducted for dilutions of 100 μM to 0.05 μM (n = 4). We identified seven compounds satisfying 
the hit criteria of IC50 < 20 μM with clear dose-response relationship as shown in Figure S6 of the supporting 
information. The chemical structures of the seven hits are given in Table 2.
We first noticed that Z56773446 and Z21813138 were found only through primary screening without NAD+; 
on the other hand, Z165047618 and Z62466600 were found only through primary screening with NAD+. To 
confirm whether the results of primary screenings of Z56773446 and Z21813138 with NAD+ and Z165047618 
and Z62466600 without NAD+ were false negatives or not, we conducted additional experiments of TSA on 
Z165047618 and Z21813138 with NAD+ (n = 4) and Z56773446 and Z62466600 without NAD+ (n = 4). We 
confirmed that the ΔTm values of Z165047618, Z21813138, and Z56773446 were not as large as the hit criterion, 
i.e., −0.03, 0.32, and −0.05, respectively. However, the ΔTm of Z62466600 was 0.87, and its hit confirmation 
and dose-dependence of the three concentrations were also confirmed. Hence, we decided that the first primary 
screening of Z62466600 was a false negative and that it should be classified as an IC50 hit (w/ & w/o NAD+). It is 
not clear why results that were shown in Fig. 1c were obtained, based on the limited information of the present 
study.
The seven hit compounds were compared to the pan-assay interference compounds (PAINS) filters,55 which 
collects substructures of frequent hitters that appeared in many biochemical high-throughput screenings. As a 
result, Z21813138, Z235344735, Z605844126, Z165049452, and Z165047618 were confirmed not to have the 
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potential problematic substructures. This result indicates that these compounds are promising candidates for 
further investigation. On the other hand, Z56773446 and Z62466600 were found to have potentially problematic 
substructures, i.e., Z56773446 has a divinylketone (PAINS filter entry: ene_one_ene_A), and Z62466600 contains 
alkylidene barbiturate (PAINS filter entry: ene_six_het_A). Despite of these potentially problematic substruc-
tures, we regarded these compounds as hit compounds, because there are known inhibitors similar to them, as 
shown in Table 2, and these compounds passed the counterscreening on unrelated protein targets. Note that the 
ΔTm values of Z56773446 and Z62466600 at 5, 10, and 20 μM (determined without NAD+) were as follows: For 
Z56773446, Sirtuin 1: 0.4, 0.6, 1.0; CA: 0.2, 0.5, 0.5; and ABL1: 0.0, 0.1, 0.2; and for Z62466600, Sirtuin 1: 0.2, 0.3, 
0.5; CA: 0.0, 0.0, 0.0; and ABL1: −0.2, 0.1, 0, respectively.
Information of the assayed compounds is given in the supporting information, including the results of ΔTm, 
dose-dependence check, selectivity, inhibition rates, and IC50 values.
Discussion
Hit rate of assayed compounds. Among 3,192 assayed compounds, 7 and 4 compounds showed IC50 
values less than 20 μM and 10 μM, respectively, as shown in Table 2. To evaluate the success odds of the contest, 
we compared this value (4/3192) with a hit rate obtained from a previous HTS study on inhibitors against recom-
binant Sirtuin 1. Therein, 58 inhibitors with an IC50 less than 10 μM were identified from among 147,000 different 
compounds56. Thus, the success odds of the contest (0.13% = 4/3192) under the same hit definition was higher 
than that reported previously (0.04%). To determine whether this improvement is statistically significant, we per-
formed an exact binomial test with a significance level of 0.05. The p-value of the test was 0.04 and less than the 
defined significance level. Although the previously applied experimental conditions and compound library were 
not identical to the contest, the results indicated that a contest-based approach would be successful in comparison 
with a simple HTS even in the hit rate. The total hit rate in this study, 7/3192, was lower than that of the previous 
contest, 11/1991, which targeted the tyrosine-protein kinase Yes when IC50 < 20 μM. This reduction in the hit rate 
may have resulted from a greater difficulty in identifying an inhibitor of the target molecule, i.e., the hit rate for 
HTS of Sirtuin 1 (0.04%)56 was lower than that for kinase (0.06%)1.
The most successful methods in terms of the hit rate have been proposed by G6 and G13, both of which 
identified two hits. The performance of these methods, relative to that of other methods, was evaluated using the 
binomial test. Provided that the average hit rate was 7/3192, the p-values of G6 and G13 were both 0.07; hence, 
Figure 1. (a) A flowchart of the contest. Each group (G1-G16) proposed 400 compounds (cmpds) with a 
prioritized rank from compound library using their own methods. The proposed compounds that were not 
stocked-out were selected until the number of compounds reached 200 for each group. If there was duplication 
in the proposed compounds among different groups, these groups attained additional compounds to be assayed. 
For this reason, there are differences among the number of selected compounds of each group. Finally, the 
selected compounds were assayed. (b) The screening flow of the compounds in the experimental assay. The 
filtering criteria are shown in a trapezium. The number of compounds applied to each screening is shown in 
parenthesis. This flow was conducted twice with NAD+ (the first number in parenthesis) and without NAD+ 
(the second number in parenthesis). (c) IC50 hits found based on TSA screening without (w/o) and with (w/) 
NAD+ (see Screening of potential inhibitors in the main text).
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they may not be considered promising methods relative to the other methods. Assuming that the success odds of 
the HTS study, 0.04%, can be considered the baseline for random screening, a hit rate of 2/181 of G6 under the hit 
criterion of IC50 < 10 μM yielded a p-value of 0.0025. Even with Bonferroni correction, this p-value indicated that 
the method of G6 is statistically promising (the p-value < 0.05/16) than the HTS.
In this study, we do not review each method in detail, but rather, we present an overview of the contest-based 
approach for the identification of potential inhibitors for the target molecule.
Diversity of proposed compounds. We have repeatedly emphasized that the contest-based approach real-
ized diversification in the screening results in terms of the chemical diversity of the assayed compounds.9,10 This 
observation was applicable to the present results, as shown in Fig. 2. The average similarity of the different com-
pounds in each group, 0.44 ± 0.09 (average and standard deviation of 16 methods, diagonal elements of Fig. 2b, 
of which values are summarized in Table S2), was higher than the average similarity of the different compounds 
in all groups, 0.36 ± 0.08 (average and standard deviation of 120 + 16 combinations, off-diagonal and diagonal 
elements of Fig. 2b), i.e., the p-value of Welch’s t-test with the null hypothesis that the two averages are equal was 
Compound 
ID Chemical Structureb
IC50 
μM
95% CI μM
Group
Similar compound ID & Chemical 
structure Similarityc & Inhibitionlower upper
Z56773446 4.1 1.9 8.9 6 (LB)
 
CHEMBL260149 (Compound 4b)57
0.95 (Inh. rate@25 μM: 
50%)57
Z62466600* 7.1 3.0 17 6,12,13 (LB)
 
CHEMBL1714005 (Compound 18),58 
CHEMBL1483080 (Compound 3)59
0.78 (IC50: 6 μM)58 (IC50: 
5.9 μM)59
Z235344735 7.6 6.4 9.1 15 (Hybrid)
 
CHEMBL449117
0.64 (Inhibition 
rate@200 μM: 28%)69
Z21813138 7.7 6.4 9.3 3 (LB)
 
CHEMBL2436120
0.65 (Inh. rate@40 μM: 
70%)70
Z165049452 12 9.3 14 13 (Hybrid)
 CHEMBL2332048
0.68 (IC50> 50 μM d)35
Z165047618* 13 7.6 23 9 (SB)
 
CHEMBL1762050
0.60 (Inh. rate@50 μM = 
70%)71
Z605844126 15 10 22 1 LB->SB
 
CHEMBL3222149
0.65 (Inh. 
rate@100 μM = 10%)72
Table 2. IC50 values of hit compoundsa and their similar known inhibitors. a) The melting temperature shift 
(ΔTm) of Sirtuin 1 upon addition of a test compound and the inhibition rates are shown in the Supporting 
Information along with the canonical SMILES. The final Sirtuin 1 concentrations used for the IC50 
determination were 30 nM for compounds marked with * and 20 nM for the others. b) The stereochemistry 
of compounds was not determined. c) Similarity scores were calculated using the Tanimoto coefficients of the 
MACCS descriptor. d) This compound was included as a known inhibitor despite its weak potency, because the 
series of its analogues are inhibitors.35 IC50 = inhibitory concentrations; CI = confidence interval.
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0.005. In addition, as seen in Tables S2 and S3, we did not observe that a specific filter class mainly contribute to 
diversifying screened compounds.
There were two groups that showed higher diversity than the average of all groups, i.e., G3 (LB approach) and 
G11 (SB approach), of which average diversities of assayed compounds were 0.30 and 0.33, respectively. Even 
though the two methods’ average diversities were higher than the average of all groups, each method typically 
yielded compounds from different places in the chemical space of the compound library, as visualized in Fig. 2c, 
indicating that the contest-based approach can realize diversified screening.
The final hit compounds were also chemically diverse, as seen in Table 2. The maximum similarity among the 
hit compounds was 0.54, which was the score between Z56773446 and Z62466600.
Figure 2. (a) Similarity of the compounds proposed from each group. The similarity scores are defined with 
the Tanimoto coefficient of the MACCS descriptor60. The number of identical compounds proposed from 
different two groups is shown in Figure S7, which indicates that identical compounds were rarely proposed from 
different groups, except for the combinations of G6 and G12 (19 compounds) and G6 and G13 (5 compounds), 
which used ligand information. (b) Averaged similarity scores in each cell of (a), in which identical compounds 
on the diagonal are not included for averaging. (c) Assayed compounds from each group are projected to the 
first and second principal components (PC1: x-axis, PC2: y-axis). Hit compounds are projected to PC1 and 
PC2 as well. Principal component analysis was applied to the compound library using the MACCS descriptor. 
The cumulative variance of the PC1 and PC2 are 26% and 50%, respectively. A randomly chosen 3% of the 
compounds in the library are projected (gray points).
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Novelty of the assayed and hit compounds. Finding chemically novel compounds in the early stage of 
drug discovery process is crucially important. To evaluate the performance of the contest-based approach to find 
such compounds, we compared the hits to the known inhibitors of Sirtuin 1. The known inhibitors in this study 
were collected from ChEMBL version 20 with queries of Standard type including IC, EC, or inhibition and were 
then filtered by the criteria of an inhibition rate less than 0% or an IC50 greater than 100 μM. Removing duplicates, 
892 unique inhibitors were identified. The inhibitor set included Sirtuin 1 ligands defined in the MUBD-HDACs 
database15 except a compound (ChEMBL ID CHEMBL99779). In this study, the compound was not defined as 
an inhibitor, because relevant information for the compound regarding inhibition of Sirtuin 1 was not found in 
ChEMBL and BindingDB.
First, we evaluated the average similarity of assayed compounds to the known inhibitors. The average similar-
ities were 0.33 ± 0.02, 0.24 ± 0.06, and 0.34 ± 0.01 for LB, SB, or hybrid methods, respectively. These values were 
low, and each filter class proposed novel compounds on average.
Thereafter, we investigated similarities among hit compounds with the known inhibitors. We regard that 
Z235344735, Z21813138, Z165049452, Z165047618, and Z605844126 are novel, because their maximum similar-
ity to known compounds was 0.68, and comparison of the chemical structures between a hit and the correspond-
ing inhibitor were not similar as shown in Table 2. Among them, four compounds were proposed from methods 
that use ligand information (LB, hybrid, LB- > SB methods) (G1, G3, G13, G15), and one compound, from the 
SBVS method (G9). This means that the use of ligand information does not necessarily yield similar compounds 
to known inhibitors. The most novel compound (Z165047618) was proposed from SBVS. However, the potency 
of the hit was classified as weak among the seven hits, as shown in Fig. 3. In the previous study, novel but weak hits 
were also found from SBVS10. Hence, novelty and potency tend to display a tradeoff association.
The remaining two compounds were similar to the known inhibitors, as shown in Table 2. The similar known 
compound of Z56773446 was reported as compound 4b57 (Tanimito coefficient of the MACCS descriptor was 
0.95). In the literature, the authors evaluated the effect of 4b on apoptosis induction and granulocytic differ-
entiation in the human leukemia U937 cells and found high differentiating activity. Hence, cell-based assay of 
Z56773446 is considered interesting. Similar known compounds of Z62466600 were reported as compound 1858 
and compound 359 in two studies (both Tanimoto coefficients were 0.78). Compound 18 was derived from opti-
mizing Cambinol, a sirtuin inhibitor that shows antitumor activity in preclinical models. Compound 18 showed 
selectivity for Sirtuin 1 (Sirtuin 1 IC50 = 6 μM, and Sirtuin 2 IC50 = 20 μM). Compound 3 showed selectivity for 
Sirtuin 1 (Sirtuin 1 IC50 = 5.9 μM, Sirtuin 2 IC50 = 20.3 μM, Sirtuin 3 inhibition rate = 14% at 50 μM, Sirtuin 5 
IC50 = 46.5 μM). Hence, further investigation of Z62466600 would be valuable.
conclusion
A compound screening contest was conducted to identify inhibitors of Sirtuin 1. Seven inhibitors were identified 
with highly diverse structures. Assuming that the hit rate of a reported HTS study56 is potentially applicable as a 
baseline for random screening, the contest-based approach could be considered significantly better than the 
HTS. The diversity could be attained by the collection of various methods in this approach. This observation was 
consistent with the previous contests. We speculated that prospective benchmarking of various methods based on 
the identical conditions (the compound library, experimental conditions, time period of proposal) would enable 
identifying a promising method for finding inhibitors of the target molecule. However, none of the proposed 
methods were better than the others on comparing them on the basis of the average hit rate determined from 
all methods, probably because of increased difficulty in identifying a novel inhibitor for Sirtuin 1 rather than the 
target of the previous contest, wherein a promising method was reported. Under these circumstances, an increase 
in the number of compounds assayed from a group would help identify a promising method. Furthermore, on 
comparing the proposed methods with low hit rates, consideration of not only hit rates but also potency of hits 
could be useful.
Figure 3. The similarity of each hit compound to known Sirtuin 1 inhibitors (see Novelty of the assayed and 
hit compounds Section) is plotted against the experimental inhibition activity. The error bar represents 95% 
confidence intervals estimated from IC50 assays. For each point, the category of method used is presented (see 
Table 1). The similarity in the figure was calculated with the Tanimoto coefficient of the MACCS descriptor60.
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